Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf443 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Manon Launay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Médecine Intensive Réanimation, CHU de Saint-Etienne, Saint-Etienne, France. Hauptthemen laut MEDLINE: Trimethoprim, Sulfamethoxazole Drug Combination, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Themen: Intensivpflege
Abstract (Originalsprache)
Background
Cotrimoxazole (trimethoprim/sulfamethoxazole) is a widely used antibiotic in ICU for the treatment of infections such as nosocomial or Pneumocystis jirovecii pneumonia. However, dosing in ICU patients is complicated by fluctuations in renal function, particularly acute kidney injury and augmented renal clearance, which affect drug elimination. This study investigated how renal function and body weight influence trimethoprim and sulfamethoxazole concentrations. Patients and methods This retrospective bicentre observational study involved 116 ICU patients receiving cotrimoxazole therapy with routine therapeutic drug monitoring. The study focused on effects of estimated glomerular filtration rate (eGFR) and weight on concentrations and dosing.
Results
Dosing of sulfamethoxazole and trimethoprim was significantly lower in patients with eGFR <30 mL/min/1.73 m2, as recommended. In these patients, sulfamethoxazole concentrations were reduced, suggesting underdosing, while trimethoprim increased with worsening renal function, indicating overdose risk when eGFR <60 mL/min/1.73 m2. Patients on renal replacement therapy (RRT) had lower sulfamethoxazole concentrations and a reduced dose-normalized C/D ratio, raising underdosing risk during RRT. trimethoprim was less affected by RRT, supporting dose reduction regardless of RRT status. No C/D ratio difference was seen between obese and non-obese patients. Weight influenced sulfamethoxazole but not trimethoprim.
Conclusions
These findings underscore the need for individualized dosing in ICU patients, especially in patients with renal impairment or RRT. Current fixed-dose combination may not adequately reflect cotrimoxazole’s complex pharmacokinetics in critical illness, stressing the importance of tailored strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Médecine Intensive Réanimation, CHU de Saint-Etienne, Saint-Etienne, France.
- Aix Marseille University, APHM, INSERM, Service de Pharmacologie Clinique et Pharmacosurveillance, INS Institute Neuroscience Syst, Marseille, France.
- Research on Healthcare Performance RESHAPE, INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.
- INSERM U1059 Sainbiose, Université Jean Monnet, Saint-Etienne F-42023, France.
ORCID-Profile: Manon Launay, Sophie Perinel Ragey
Zitieren
APA
Launay, M., Pina, M., Guilhaumou, R., Bruna, F., Thiery, G., & Perinel Ragey, S. (2026). Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf443
Vancouver
Launay M, Pina M, Guilhaumou R, Bruna F, Thiery G, Perinel Ragey S. Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf443
BibTeX
@article{Launay2026,
author = {Launay, Manon and Pina, Maxime and Guilhaumou, Romain and Bruna, Franklin and Thiery, Guillaume and Perinel Ragey, Sophie},
title = {Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf443}
}
EUVIMED